Older adults receiving the GLP-1 agonist semaglutide showed less worsening in a protein-based dementia forecast than those receiving placebo.
“The drug mimics GLP-1, a hormone that helps the pancreas release insulin and the brain regulate appetite. But certain cells in the heart, blood vessels, and other tissues also carry GLP-1 receptors, allowing them to respond to the same signal.”